
|Articles|April 1, 2004
Levofloxacin 1.5% earns FDA approval
Minneapolis, MN-The new fluoroquinolone, levofloxacin 1.5% ophthalmic solution (IQUIX, Santen), has received FDA approval to be marketed for the treatment of bacterial corneal ulcer. The approval brings with it a milestone as the first current-generation fluoroquinolone with an indication for use in the management of that sight-threatening condition, explained Richard L. Lindstrom, MD.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Eyes on May 2026: A month of durable therapies, a regulatory reversal, and rethought echanisms
2
Reasoning prompts sharpen multimodal AI on bilingual ophthalmology exam questions
3
TECNIS PureSee IOL launches in US following FDA approval for cataract surgery
4
Beyond the Walls: Leading with love, loyalty, and a team first philosophy with Vance Thompson, MD
5





















